(Q37999649)

26 August 2017

title

Monitoring the safety of medicines used off-label (English)

1 reference

26 August 2017

G J Dal Pan

1

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 May 2012

1 reference

Clinical Pharmacology & Therapeutics

26 August 2017

published in

1 reference

26 August 2017

volume

91

1 reference

26 August 2017

issue

5

1 reference

26 August 2017

page(s)

787-795

1 reference

Off-label prescribing among office-based physicians

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

Frequency of ill-founded off-label prescribing in Dutch general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

Self-reported practices and attitudes of US oncologists regarding off-protocol therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

Off-label prescribing to children in the United States outpatient setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

Drug use in children: cohort study in three European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

Off-label drug use in hospitalized children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

Seizure activity and off-label use of tiagabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

Safety monitoring of drugs receiving pediatric marketing exclusivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

Clinical end points in coronary stent trials: a case for standardized definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

Spontaneous reports of thrombocytopenia in association with quinine: clinical attributes and timing related to regulatory action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

Duration of therapy with metoclopramide: a prescription claims data study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

Enhancing pharmacosurveillance with systematic collection of treatment indication in electronic prescribing: a validation study in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

Web-based intensive monitoring: from passive to active drug surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

Patient-reported outcomes as a source of evidence in off-label prescribing: analysis of data from PatientsLikeMe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

7 January 2021

Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

7 January 2021

Randomised controlled trial of hydroquinine in muscle cramps

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

7 January 2021

Contraindicated use of cisapride: impact of food and drug administration regulatory action

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.24

7 January 2021

Identifiers

DOI

10.1038/CLPT.2012.24

1 reference

26 August 2017

1 reference